Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations

[ad_1] -Application to add ~200 non-F508del CFTR mutations to the KAFTRIO® license- -If approved, ~2,800 people with cystic fibrosis in the European Union ages 2 and above could receive a…